Elevated expression of prostaglandin E2 synthetic pathway in skeletal muscle of prior polio patients

Journal of Rehabilitation Medicine

Volumn 46, Issue 1, 2014, Pages 67-72

  Melin, Eva ^a   Lindroos, Eva ^b   Lundberg, Ingrid E ^b   Borg, Kristian ^a   Korotkova, Marina ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Actar AB   (Sweden)

Author keywords

Neuromuscular diseases; Post polio syndrome; Prostaglandin E2; Skeletal muscle

Indexed keywords

PROSTAGLANDIN E2;

ADULT; ARTICLE; BIOSYNTHESIS; FATIGUE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUSCLE WEAKNESS; MYALGIA; POLIOMYELITIS; POSTPOLIOMYELITIS SYNDROME; SKELETAL MUSCLE; YOUNG ADULT;

ADULT; DINOPROSTONE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYALGIA; POLIOMYELITIS; POSTPOLIOMYELITIS SYNDROME; YOUNG ADULT;

EID: 84891847690     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-1230     Document Type: Article

References (39)

1. Halstead LS, Rossi CD. Post-polio syndrome: clinical experience with 132 consecutive outpatients. Birth Defects Orig Artic Ser 1987; 23: 13-26.
2. Rowland LP. Post-polio syndrome: identifying best practices in diagnosis & care. 2001 [cited 1999 Oct]. Available from: http://www.marchofdimes.com/ downloads/PostPolio.pdf.
3. Halstead LS. Assessment and differential diagnosis for post-polio syndrome. Orthopedics 1991; 14: 1209-1217.
4. Borg K. Post-polio muscle dysfunction 29th ENMC workshop 14-16 October 1994, Naarden, The Netherlands. Neuromuscul Disord 1996; 6: 75-80.
5. Grimby G, Stalberg E, Sandberg A, Sunnerhagen KS. An 8-year longitudinal study of muscle strength, muscle fiber size, and dynamic electromyogram in individuals with late polio. Muscle Nerve 1998; 21: 1428-1437.
6. Perry J, Barnes G, Gronley JK. The postpolio syndrome. An overuse phenomenon. Clin Orthopaed Rel Res 1988; 233: 145-162.
7. Gonzalez H, Ottervald J, Nilsson KC, Sjogren N, Miliotis T, Von Bahr H, et al. Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics 2009; 71: 670-681.
8. Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 2002; 205: 9-13.
9. Sharief MK, Hentges R, Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. New Engl J Med 1991; 325: 749-755.
10. Dalakas MC. Morphologic changes in the muscles of patients with postpoliomyelitis neuromuscular symptoms. Neurology 1988; 38: 99-104.
11. Gonzalez H, Sunnerhagen KS, Sjoberg I, Kaponides G, Olsson T, Borg K. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 2006; 5: 493-500.
12. Fordyce CB, Gagne D, Jalili F, Alatab S, Arnold DL, Da Costa D, et al. Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 2008; 271: 80-86.
13. Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol 2007; 14: 60-65.
14. Werhagen L, Borg K. Effect of intravenous immunoglobulin on pain in patients with post-polio syndrome. J Rehabil Med 2011; 43: 1038-1040.
15. Borg K, Borg J, Edstrom L, Grimby L. Effects of excessive use of remaining muscle fibers in prior polio and LV lesion. Muscle Nerve 1988; 11: 1219-1230.
16. Einarsson G, Grimby G, Stalberg E. Electromyographic and morphological functional compensation in late poliomyelitis. Muscle Nerve 1990; 13: 165-171.
17. Hori T, Oka T, Hosoi M, Aou S. Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann N Y Acad Sci 1998; 840: 269-281.
18. Oka T. Prostaglandin E2 as a mediator of fever: the role of prostaglandin E (EP) receptors. Front Biosci 2004; 9: 3046-3057.
19. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathionedependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999; 96: 7220-7225.
20. Dieter P, Scheibe R, Jakobsson PJ, Watanabe K, Kolada A, Kamionka S. Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. Biochem Biophys Res Commun 2000; 276: 488-492.
21. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275: 32783-32792.
22. Matousek SB, Hein AM, Shaftel SS, Olschowka JA, Kyrkanides S, O'Banion MK. Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem 2010; 114: 247-258.
23. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000; 275: 32775-32782.
24. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003; 278: 37937-37947.
25. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007; 59: 207-224.
26. Henriksson KG. "Semi-open" muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand 1979; 59: 317-323.
27. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage- stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
28. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L,et al. Arthritis Rheum 2004; 50: 1774-1780.
29. Gonzalez H, Olsson T, Borg K. Management of postpolio syndrome. Lancet Neurol 2010; 9: 634-642.
30. Dalakas MC. The post-polio syndrome as an evolved clinical entity. Definition and clinical description. Ann N Y Acad Sci 1995; 753: 68-80.
31. Dalakas MC, Sever JL, Madden DL, Papadopoulos NM, Shekarchi IC, Albrecht P, et al. Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies. Rev Infect Dis 1984; 6 Suppl 2: S562-S567.
32. Borg K, Borg J, Dhoot G, Edstrom L, Grimby L, Thornell LE. Motoneuron firing and isomyosin type of muscle fibres in prior polio. J Neurol Neurosurg Psychiatry 1989; 52: 1141-1148.
33. Borg K, Henriksson J. Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. J Neurol Neurosurg Psychiatry 1991; 54: 236-240.
34. Semino-Mora C, Dalakas MC. Rimmed vacuoles with betaamyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 1998; 29: 1128-1133.
35. Gonzalez H, Khademi M, Andersson M, Piehl F, Wallstrom E, Borg K, et al. Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 2004; 150: 139-144.
36. Werhagen L, Borg K. Analysis of long-standing nociceptive and neuropathic pain in patients with post-polio syndrome. J Neurol 2010; 257: 1027-1031.
37. Werhagen L, Borg K. Impact of pain on quality of life in patients with post-polio syndrome. J Rehabil Med 2013; 45: 161-163.
38. Wang M, Fitzgerald GA. Cardiovascular biology of microsomal prostaglandin e synthase-1. Trends Cardiovasc Med 2010; 20: 189-195.
39. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3-27.